首页 > 最新文献

血液科学(英文)最新文献

英文 中文
Novel heterozygous mutations of TNFRSF13B in EBV-associated T/NK lymphoproliferative diseases (EBV-T/NK-LPDs). EBV相关T/NK淋巴细胞增生性疾病(EBV-T/NK-LPDs)中TNFRSF13B的新型杂合突变。
Q3 HEMATOLOGY Pub Date : 2024-01-15 eCollection Date: 2024-01-01 DOI: 10.1097/BS9.0000000000000180
Xinyue Deng, Tong Ge, Kefeng Shen, Jiachen Wang, Wei Mu, Hui Luo, Jia Gu, Meilan Zhang, Min Xiao
{"title":"Novel heterozygous mutations of <i>TNFRSF13B</i> in EBV-associated T/NK lymphoproliferative diseases (EBV-T/NK-LPDs).","authors":"Xinyue Deng, Tong Ge, Kefeng Shen, Jiachen Wang, Wei Mu, Hui Luo, Jia Gu, Meilan Zhang, Min Xiao","doi":"10.1097/BS9.0000000000000180","DOIUrl":"10.1097/BS9.0000000000000180","url":null,"abstract":"","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"6 1","pages":"e00180"},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10789450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139473111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acupoint transplantation versus non-acupoint transplantation using autologous peripheral blood mononuclear cells in treating peripheral arterial disease. 使用自体外周血单核细胞治疗外周动脉疾病的穴位移植与非穴位移植。
Q3 HEMATOLOGY Pub Date : 2024-01-15 eCollection Date: 2024-01-01 DOI: 10.1097/BS9.0000000000000175
Wenjing Guo, Ling Pan, Ruiyu Yang, Jiali Sun, Qinglin Hu, Pingping Huang

Numerous studies have discussed the therapeutic outcomes of using cell therapy or acupuncture to treat peripheral artery disease (PAD). However, there are no long-term studies on the safety and efficacy of transplanting peripheral blood mononuclear cells (PBMNCs) via acupoints to treat PAD. We first reviewed the short-term and long-term clinical results of PAD patients treated with PBMNCs through intramuscular non-acupoint transplantation (control group; n = 45) or intramuscular acupoint transplantation (acupoint group; n = 45) at a single university hospital general medical center between December 2002 and September 2022. Pain intensity (assessed with the verbal rating scale [VRS] score) in the acupoint group was considerably lower than that in the control group at month 1 (mean ± standard deviation [SD]: 1.29 ± 0.96 vs 1.76 ± 0.82; P = 0.016) and month 3 (mean ± SD: 1.27 ± 0.90 vs 1.61 ± 0.86; P = 0.042). We observed significant improvement of VRS score (P < .001 for all) and ankle-brachial index (ABI; P < .001 for all) from baseline in both groups at months 1, 3, 6, 12, 36, and 60. The 10-year cumulative rate of major amputation-free survival (MAFS) was higher in the acupoint group as compared to the control group (81.9%, 95% confidence interval [CI]: 71.3%-94.1% vs 78.5%, 95% CI: 66.7%-92.3%; P = 0.768). Compared with the routine injection method, intramuscular transplantation of PBMNCs via selected acupoints could significantly decrease the short-term pain intensity in patients with PAD, which remains an option for consideration.

许多研究讨论了使用细胞疗法或针灸治疗外周动脉疾病(PAD)的疗效。然而,目前还没有关于通过穴位移植外周血单核细胞(PBMNC)治疗 PAD 的安全性和有效性的长期研究。我们首先回顾了2002年12月至2022年9月期间在一家大学医院综合医疗中心通过肌肉注射非穴位移植(对照组;n = 45)或肌肉注射穴位移植(穴位组;n = 45)用PBMNCs治疗PAD患者的短期和长期临床结果。在第 1 个月(平均值±标准差[SD]:1.29±0.96 vs 1.76±0.82;P = 0.016)和第 3 个月(平均值±标准差:1.27±0.90 vs 1.61±0.86;P = 0.042),穴位组的疼痛强度(用口头评分量表[VRS]评分评估)明显低于对照组。我们观察到,在第 1、3、6、12、36 和 60 个月时,两组患者的 VRS 评分(P < .001)和踝肱指数(ABI;P < .001)均较基线有明显改善。与对照组相比,穴位组的 10 年无截肢累积存活率(MAFS)更高(81.9%,95% 置信区间 [CI]: 71.3%-94.1% vs 78.5%,95% CI: 66.7%-92.3%; P = 0.768)。与常规注射方法相比,通过选定穴位肌肉移植 PBMNCs 可显著降低 PAD 患者的短期疼痛强度,仍是一个值得考虑的选择。
{"title":"Acupoint transplantation versus non-acupoint transplantation using autologous peripheral blood mononuclear cells in treating peripheral arterial disease.","authors":"Wenjing Guo, Ling Pan, Ruiyu Yang, Jiali Sun, Qinglin Hu, Pingping Huang","doi":"10.1097/BS9.0000000000000175","DOIUrl":"10.1097/BS9.0000000000000175","url":null,"abstract":"<p><p>Numerous studies have discussed the therapeutic outcomes of using cell therapy or acupuncture to treat peripheral artery disease (PAD). However, there are no long-term studies on the safety and efficacy of transplanting peripheral blood mononuclear cells (PBMNCs) via acupoints to treat PAD. We first reviewed the short-term and long-term clinical results of PAD patients treated with PBMNCs through intramuscular non-acupoint transplantation (control group; n = 45) or intramuscular acupoint transplantation (acupoint group; n = 45) at a single university hospital general medical center between December 2002 and September 2022. Pain intensity (assessed with the verbal rating scale [VRS] score) in the acupoint group was considerably lower than that in the control group at month 1 (mean ± standard deviation [SD]: 1.29 ± 0.96 vs 1.76 ± 0.82; <i>P</i> = 0.016) and month 3 (mean ± SD: 1.27 ± 0.90 vs 1.61 ± 0.86; <i>P</i> = 0.042). We observed significant improvement of VRS score (<i>P</i> < .001 for all) and ankle-brachial index (ABI; <i>P</i> < .001 for all) from baseline in both groups at months 1, 3, 6, 12, 36, and 60. The 10-year cumulative rate of major amputation-free survival (MAFS) was higher in the acupoint group as compared to the control group (81.9%, 95% confidence interval [CI]: 71.3%-94.1% vs 78.5%, 95% CI: 66.7%-92.3%; <i>P</i> = 0.768). Compared with the routine injection method, intramuscular transplantation of PBMNCs via selected acupoints could significantly decrease the short-term pain intensity in patients with PAD, which remains an option for consideration.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"6 1","pages":"e00175"},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10789451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139473104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sequential infusion of two different chimeric antigen receptor T cells: induction of a deep and durable remission. 连续输注两种不同的嵌合抗原受体 T 细胞:诱导深度和持久缓解。
Q3 HEMATOLOGY Pub Date : 2024-01-10 eCollection Date: 2024-01-01 DOI: 10.1097/BS9.0000000000000177
Kailin Xu
{"title":"Sequential infusion of two different chimeric antigen receptor T cells: induction of a deep and durable remission.","authors":"Kailin Xu","doi":"10.1097/BS9.0000000000000177","DOIUrl":"10.1097/BS9.0000000000000177","url":null,"abstract":"","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"6 1","pages":"e00177"},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10781117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139426189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hematopoietic stem cell heterogeneity in non-human primates revealed by five-lineage output bias analysis. 通过五系输出偏差分析揭示非人灵长类的造血干细胞异质性。
Q3 HEMATOLOGY Pub Date : 2024-01-10 eCollection Date: 2024-01-01 DOI: 10.1097/BS9.0000000000000176
Man Zhang, Di Liu, Yu Lan, Bing Liu, Zongcheng Li, Yanli Ni

Understanding hematopoietic stem cell (HSC) heterogeneity is crucial for treating malignant blood disorders. Compared with mice, we have limited knowledge of the heterogeneity of human HSCs. Fortunately, non-human primates (NHPs) have become the best animal models for studying human HSCs. Here, we employed a public dataset derived from NHP autologous bone marrow transplantation, and focused on a total of 820 HSC clones with reconstitution capacity of all available five lineages (granulocyte, monocyte, B cell, T cell, and natural killer cell) at two time points (11/12 and/or 42/43 months). Intriguingly, unsupervised clustering on these clones revealed six HSC subtypes, including a lymphoid/myeloid balanced (LM-balanced) subtype and five single-lineage-biased subtypes. We also observed that the subtypes of these HSC clones might change over time, and a given subtype could transition into any one of the other five subtypes, albeit with a certain degree of selectivity. Particularly, each of the six subtypes was more likely to turn into lymphoid-biased rather than myeloid-biased ones. Additionally, our five-lineage classification method exhibited strong correlation with traditional lymphoid/myeloid bias classification method. Specifically, our granulocyte- and monocyte-biased subtypes were predominantly attributed to α-HSCs, while LM-balanced, B cell-biased, and T cell-biased subtypes were primarily associated with β-HSCs. The γ-HSCs were composed of a small subset of B cell-biased and T cell-biased subtypes. In summary, our five-lineage classification identifies more finely tuned HSC subtypes based on lineage output bias. These findings enrich our understanding of HSC heterogeneity in NHPs and provide important insights for human research.

了解造血干细胞的异质性对治疗恶性血液疾病至关重要。与小鼠相比,我们对人类造血干细胞异质性的了解十分有限。幸运的是,非人灵长类动物(NHP)已成为研究人类造血干细胞的最佳动物模型。在这里,我们使用了一个来自非人灵长类动物自体骨髓移植的公开数据集,重点研究了在两个时间点(11/12 个月和/或 42/43 个月)总共 820 个具有重组能力的造血干细胞克隆的所有可用的五个系(粒细胞、单核细胞、B 细胞、T 细胞和自然杀伤细胞)。有趣的是,对这些克隆进行无监督聚类发现了六种造血干细胞亚型,包括一种淋巴细胞/骨髓细胞平衡亚型(LM-平衡)和五种单系偏向亚型。我们还观察到,这些造血干细胞克隆的亚型可能会随着时间的推移而发生变化,特定亚型可能会转变为其他五种亚型中的任何一种,尽管具有一定程度的选择性。特别是,六种亚型中的每一种都更有可能转变为淋巴细胞型而非髓细胞型。此外,我们的五系分类方法与传统的淋巴/骨髓偏向分类方法有很强的相关性。具体来说,我们的粒细胞偏向和单核细胞偏向亚型主要归因于α-造血干细胞,而LM平衡、B细胞偏向和T细胞偏向亚型主要与β-造血干细胞有关。γ-造血干细胞由B细胞偏向亚型和T细胞偏向亚型的一小部分组成。总之,我们的五系分类根据系输出偏向确定了更精细的造血干细胞亚型。这些发现丰富了我们对 NHPs 中造血干细胞异质性的认识,并为人类研究提供了重要启示。
{"title":"Hematopoietic stem cell heterogeneity in non-human primates revealed by five-lineage output bias analysis.","authors":"Man Zhang, Di Liu, Yu Lan, Bing Liu, Zongcheng Li, Yanli Ni","doi":"10.1097/BS9.0000000000000176","DOIUrl":"10.1097/BS9.0000000000000176","url":null,"abstract":"<p><p>Understanding hematopoietic stem cell (HSC) heterogeneity is crucial for treating malignant blood disorders. Compared with mice, we have limited knowledge of the heterogeneity of human HSCs. Fortunately, non-human primates (NHPs) have become the best animal models for studying human HSCs. Here, we employed a public dataset derived from NHP autologous bone marrow transplantation, and focused on a total of 820 HSC clones with reconstitution capacity of all available five lineages (granulocyte, monocyte, B cell, T cell, and natural killer cell) at two time points (11/12 and/or 42/43 months). Intriguingly, unsupervised clustering on these clones revealed six HSC subtypes, including a lymphoid/myeloid balanced (LM-balanced) subtype and five single-lineage-biased subtypes. We also observed that the subtypes of these HSC clones might change over time, and a given subtype could transition into any one of the other five subtypes, albeit with a certain degree of selectivity. Particularly, each of the six subtypes was more likely to turn into lymphoid-biased rather than myeloid-biased ones. Additionally, our five-lineage classification method exhibited strong correlation with traditional lymphoid/myeloid bias classification method. Specifically, our granulocyte- and monocyte-biased subtypes were predominantly attributed to α-HSCs, while LM-balanced, B cell-biased, and T cell-biased subtypes were primarily associated with β-HSCs. The γ-HSCs were composed of a small subset of B cell-biased and T cell-biased subtypes. In summary, our five-lineage classification identifies more finely tuned HSC subtypes based on lineage output bias. These findings enrich our understanding of HSC heterogeneity in NHPs and provide important insights for human research.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"6 1","pages":"e00176"},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10781131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139426188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation. 造血干细胞移植后预防巨细胞病毒感染的勒替莫韦的有效性和安全性。
Q3 HEMATOLOGY Pub Date : 2024-01-10 eCollection Date: 2024-01-01 DOI: 10.1097/BS9.0000000000000178
Wen-Wen Li, Yong-Mei Zhang, Meng-Zhu Shen, Xiao-Dong Mo

Letermovir is a specific inhibitor of cytomegalovirus (CMV) terminase complex. Several studies have reported that letermovir can effectively prevent CMV activation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aimed to identify the efficacy and safety of letermovir prophylaxis for CMV infection after allo-HSCT with a systemic review and meta-analysis. A literature search was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. PubMed and Embase databases were searched. A total of 28 studies were included. The incidence of CMV activation at 14 weeks after HSCT was 0.10 (95% confidence interval [CI], 0.06-0.18), which was 0.10 (95% CI, 0.04-0.21) and 0% in adult and children (2 studies were included and both of them were 0%). In addition, the incidence of CMV activation at 14 weeks after allo-HSCT was 0.11 (95% CI, 0.06-0.21) and 0.07 (only 1 study included), respectively, in retrospective and prospective studies. The incidence of CMV activation at 100 and 200 days after HSCT was 0.23 (95% CI, 0.16-0.33) and 0.49 (95% CI, 0.32-0.67), respectively. The incidence of CMV disease at 14 weeks and at 6 months after HSCT was 0.01 (95% CI, 0.01-0.02) and 0.03 (95% CI, 0.01-0.09), respectively. Thus, our systemic review and meta-analysis suggested that letermovir prophylaxis was safe and effective for CMV activation after allo-HSCT.

来替莫韦是巨细胞病毒(CMV)终结酶复合物的特异性抑制剂。多项研究表明,来替莫韦能有效预防异基因造血干细胞移植(allo-HSCT)后的CMV激活。我们的目的是通过系统综述和荟萃分析来确定allo-HSCT后预防CMV感染的效果和安全性。按照《系统综述和荟萃分析首选报告项目》声明进行了文献检索。检索了 PubMed 和 Embase 数据库。共纳入 28 项研究。造血干细胞移植后 14 周时,CMV 激活的发生率为 0.10(95% 置信区间 [CI],0.06-0.18),成人为 0.10(95% 置信区间 [CI],0.04-0.21),儿童为 0%(纳入 2 项研究,均为 0%)。此外,在回顾性研究和前瞻性研究中,allo-HSCT 后 14 周 CMV 激活的发生率分别为 0.11(95% CI,0.06-0.21)和 0.07(仅纳入 1 项研究)。造血干细胞移植后100天和200天的CMV激活发生率分别为0.23(95% CI,0.16-0.33)和0.49(95% CI,0.32-0.67)。造血干细胞移植后14周和6个月时CMV疾病的发生率分别为0.01(95% CI,0.01-0.02)和0.03(95% CI,0.01-0.09)。因此,我们的系统综述和荟萃分析表明,在allo-HSCT后预防CMV激活是安全有效的。
{"title":"Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation.","authors":"Wen-Wen Li, Yong-Mei Zhang, Meng-Zhu Shen, Xiao-Dong Mo","doi":"10.1097/BS9.0000000000000178","DOIUrl":"10.1097/BS9.0000000000000178","url":null,"abstract":"<p><p>Letermovir is a specific inhibitor of cytomegalovirus (CMV) terminase complex. Several studies have reported that letermovir can effectively prevent CMV activation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aimed to identify the efficacy and safety of letermovir prophylaxis for CMV infection after allo-HSCT with a systemic review and meta-analysis. A literature search was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. PubMed and Embase databases were searched. A total of 28 studies were included. The incidence of CMV activation at 14 weeks after HSCT was 0.10 (95% confidence interval [CI], 0.06-0.18), which was 0.10 (95% CI, 0.04-0.21) and 0% in adult and children (2 studies were included and both of them were 0%). In addition, the incidence of CMV activation at 14 weeks after allo-HSCT was 0.11 (95% CI, 0.06-0.21) and 0.07 (only 1 study included), respectively, in retrospective and prospective studies. The incidence of CMV activation at 100 and 200 days after HSCT was 0.23 (95% CI, 0.16-0.33) and 0.49 (95% CI, 0.32-0.67), respectively. The incidence of CMV disease at 14 weeks and at 6 months after HSCT was 0.01 (95% CI, 0.01-0.02) and 0.03 (95% CI, 0.01-0.09), respectively. Thus, our systemic review and meta-analysis suggested that letermovir prophylaxis was safe and effective for CMV activation after allo-HSCT.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"6 1","pages":"e00178"},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10781138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139426187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Essential procedures of single-cell RNA sequencing in multiple myeloma and its translational value. 多发性骨髓瘤单细胞RNA测序的基本程序及其翻译价值。
Q3 HEMATOLOGY Pub Date : 2023-11-02 eCollection Date: 2023-10-01 DOI: 10.1097/BS9.0000000000000172
Jun Du, Xiao-Ran Gu, Xiao-Xiao Yu, Yang-Jia Cao, Jian Hou

Multiple myeloma (MM) is a malignant neoplasm characterized by clonal proliferation of abnormal plasma cells. In many countries, it ranks as the second most prevalent malignant neoplasm of the hematopoietic system. Although treatment methods for MM have been continuously improved and the survival of patients has been dramatically prolonged, MM remains an incurable disease with a high probability of recurrence. As such, there are still many challenges to be addressed. One promising approach is single-cell RNA sequencing (scRNA-seq), which can elucidate the transcriptome heterogeneity of individual cells and reveal previously unknown cell types or states in complex tissues. In this review, we outlined the experimental workflow of scRNA-seq in MM, listed some commonly used scRNA-seq platforms and analytical tools. In addition, with the advent of scRNA-seq, many studies have made new progress in the key molecular mechanisms during MM clonal evolution, cell interactions and molecular regulation in the microenvironment, and drug resistance mechanisms in target therapy. We summarized the main findings and sequencing platforms for applying scRNA-seq to MM research and proposed broad directions for targeted therapies based on these findings.

多发性骨髓瘤(MM)是一种以异常浆细胞克隆增殖为特征的恶性肿瘤。在许多国家,它是造血系统中第二常见的恶性肿瘤。尽管MM的治疗方法不断改进,患者的生存期显著延长,但MM仍然是一种不可治愈的疾病,复发几率很高。因此,仍有许多挑战需要解决。一种有前景的方法是单细胞RNA测序(scRNA-seq),它可以阐明单个细胞的转录组异质性,并揭示复杂组织中以前未知的细胞类型或状态。在这篇综述中,我们概述了scRNA-seq在MM中的实验工作流程,列出了一些常用的scRNA-seq平台和分析工具。此外,随着scRNA-seq的出现,许多研究在MM克隆进化的关键分子机制、微环境中的细胞相互作用和分子调控以及靶向治疗中的耐药性机制等方面取得了新的进展。我们总结了将scRNA-seq应用于MM研究的主要发现和测序平台,并基于这些发现提出了靶向治疗的广泛方向。
{"title":"Essential procedures of single-cell RNA sequencing in multiple myeloma and its translational value.","authors":"Jun Du, Xiao-Ran Gu, Xiao-Xiao Yu, Yang-Jia Cao, Jian Hou","doi":"10.1097/BS9.0000000000000172","DOIUrl":"10.1097/BS9.0000000000000172","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a malignant neoplasm characterized by clonal proliferation of abnormal plasma cells. In many countries, it ranks as the second most prevalent malignant neoplasm of the hematopoietic system. Although treatment methods for MM have been continuously improved and the survival of patients has been dramatically prolonged, MM remains an incurable disease with a high probability of recurrence. As such, there are still many challenges to be addressed. One promising approach is single-cell RNA sequencing (scRNA-seq), which can elucidate the transcriptome heterogeneity of individual cells and reveal previously unknown cell types or states in complex tissues. In this review, we outlined the experimental workflow of scRNA-seq in MM, listed some commonly used scRNA-seq platforms and analytical tools. In addition, with the advent of scRNA-seq, many studies have made new progress in the key molecular mechanisms during MM clonal evolution, cell interactions and molecular regulation in the microenvironment, and drug resistance mechanisms in target therapy. We summarized the main findings and sequencing platforms for applying scRNA-seq to MM research and proposed broad directions for targeted therapies based on these findings.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"5 4","pages":"221-236"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71524095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute intestinal GVHD following donor-derived CD7-CAR-T-cell infusion in a child with Omicron COVID-19. 一名患有奥密克戎新冠肺炎的儿童输注供体来源的CD7-CAR-T-细胞后急性肠道GVHD。
Q3 HEMATOLOGY Pub Date : 2023-11-02 eCollection Date: 2023-10-01 DOI: 10.1097/BS9.0000000000000170
Yu Lian, Zhilin Gao, Juanjuan Ti, Zhuanzhuan Yu, Liangming Ma, Jia Wei
{"title":"Acute intestinal GVHD following donor-derived CD7-CAR-T-cell infusion in a child with Omicron COVID-19.","authors":"Yu Lian, Zhilin Gao, Juanjuan Ti, Zhuanzhuan Yu, Liangming Ma, Jia Wei","doi":"10.1097/BS9.0000000000000170","DOIUrl":"10.1097/BS9.0000000000000170","url":null,"abstract":"","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"5 4","pages":"269-273"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71523548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation presenting as pericardial effusion. 异基因造血干细胞移植后急性髓系白血病复发,表现为心包积液。
Q3 HEMATOLOGY Pub Date : 2023-11-02 eCollection Date: 2023-10-01 DOI: 10.1097/BS9.0000000000000174
Yuyan Shen, Jiali Sun, Donglin Yang, Sizhou Feng
{"title":"Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation presenting as pericardial effusion.","authors":"Yuyan Shen, Jiali Sun, Donglin Yang, Sizhou Feng","doi":"10.1097/BS9.0000000000000174","DOIUrl":"10.1097/BS9.0000000000000174","url":null,"abstract":"","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"5 4","pages":"274-276"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71523549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAR-T cell therapy: Where are we now, and where are we heading? CAR-T细胞治疗:我们现在在哪里,我们将走向何方?
Q3 HEMATOLOGY Pub Date : 2023-11-02 eCollection Date: 2023-10-01 DOI: 10.1097/BS9.0000000000000173
Jia-Yi Wang, Liang Wang

Chimeric antigen receptor (CAR)-T-cell therapies have exhibited remarkable efficacy in the treatment of hematologic malignancies, with 9 CAR-T-cell products currently available. Furthermore, CAR-T cells have shown promising potential for expanding their therapeutic applications to diverse areas, including solid tumors, myocardial fibrosis, and autoimmune and infectious diseases. Despite these advancements, significant challenges pertaining to treatment-related toxic reactions and relapses persist. Consequently, current research efforts are focused on addressing these issues to enhance the safety and efficacy of CAR-T cells and reduce the relapse rate. This article provides a comprehensive overview of the present state of CAR-T-cell therapies, including their achievements, existing challenges, and potential future developments.

嵌合抗原受体(CAR)-T细胞疗法在治疗血液系统恶性肿瘤方面表现出显著疗效,目前已有9种CAR-T细胞产品可用。此外,CAR-T细胞已显示出将其治疗应用扩展到不同领域的潜力,包括实体瘤、心肌纤维化、自身免疫性和感染性疾病。尽管取得了这些进展,但与治疗相关的毒性反应和复发相关的重大挑战依然存在。因此,目前的研究工作集中在解决这些问题上,以提高CAR-T细胞的安全性和有效性并降低复发率。本文全面概述了CAR-T细胞疗法的现状,包括其成就、现有挑战和潜在的未来发展。
{"title":"CAR-T cell therapy: Where are we now, and where are we heading?","authors":"Jia-Yi Wang, Liang Wang","doi":"10.1097/BS9.0000000000000173","DOIUrl":"10.1097/BS9.0000000000000173","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR)-T-cell therapies have exhibited remarkable efficacy in the treatment of hematologic malignancies, with 9 CAR-T-cell products currently available. Furthermore, CAR-T cells have shown promising potential for expanding their therapeutic applications to diverse areas, including solid tumors, myocardial fibrosis, and autoimmune and infectious diseases. Despite these advancements, significant challenges pertaining to treatment-related toxic reactions and relapses persist. Consequently, current research efforts are focused on addressing these issues to enhance the safety and efficacy of CAR-T cells and reduce the relapse rate. This article provides a comprehensive overview of the present state of CAR-T-cell therapies, including their achievements, existing challenges, and potential future developments.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"5 4","pages":"237-248"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71524094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The opposite impact of Janus kinase inhibitor Ruxolitinib on the function of bone marrow mesenchymal stem cells and immune cells in acute GVHD recipients. Janus激酶抑制剂Ruxolitinib对急性移植物抗宿主病受者骨髓间充质干细胞和免疫细胞功能的相反影响。
Q3 HEMATOLOGY Pub Date : 2023-09-08 eCollection Date: 2023-10-01 DOI: 10.1097/BS9.0000000000000171
Defu Zeng
{"title":"The opposite impact of Janus kinase inhibitor Ruxolitinib on the function of bone marrow mesenchymal stem cells and immune cells in acute GVHD recipients.","authors":"Defu Zeng","doi":"10.1097/BS9.0000000000000171","DOIUrl":"10.1097/BS9.0000000000000171","url":null,"abstract":"","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"5 4","pages":"277-279"},"PeriodicalIF":0.0,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71523550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
血液科学(英文)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1